Skip to main content
Category

News Archive

astrazeneca-logo

AstraZeneca to invest $630 million in Korean biohealth sector – Korea Biomedical Review

By News Archive

astrazeneca-logo

AstraZeneca said it would invest $630 million into Korea’s biotech and healthcare sector over the next five years.

Leif Johansson, chairman of the British-Swedish drugmaker, announced the plan at the Korea-Sweden Business Summit, attended by President Moon Jae-in, Swedish King Carl XVI Gustaf, and Swedish Prime Minister Stefan Löfven in Stockholm on Friday, local time. The business summit was held as part of President Moon’s state visit.

Read More
viela-bio-logo

Viela Bio Closes $75 Million Series B Financing – Business Wire

By News Archive

viela-bio-logo

Viela Bio today announced the successful completion of a $75 million private placement of its Series B preferred stock, bringing the total capital raised since the Company’s launch in February 2018 to more than $300 million. The financing round was led by HBM Healthcare Investments, and additional new investors participating included Viking Global Investors, Cormorant Asset Management, Terra Magnum Capital Partners, Goldman Sachs, and Barer & Son Capital. Existing investors participating included Temasek.

Read More
CASI-Pharmaceuticals-logo

CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy

By News Archive

CASI-Pharmaceuticals-logo

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company that is focusing on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, the U.S., and throughout the world, announces the signing of a license agreement for exclusive worldwide license and commercialization rights to an autologous anti-CD19 T-cell therapy product (CNCT19) from Juventas Cell Therapy Ltd., a China-based domestic company located in Tianjin City, China. Juventas will continue to develop CNCT19 with CASI’s participation on the program’s steering committee. CASI will be responsible for payment of certain future development milestones and sales royalties.

Read More
invest-money-vc-fives-pixa

The Top 10 Highest-Paid Women Executives in Biopharma – Martine Rothblatt, Chairman of United Therapeutics #2

By News Archive

invest-money-vc-fives-pixa

After last year’s BIO International Convention in Boston was overshadowed by reports of topless women dancers bearing the logos of biopharma company sponsors at an unofficial party, the Biotechnology Innovation Organization in October sent its members a letter insisting that they pay more than lip service to diversifying their historically male executive suites and boardrooms.

Read More
nhlbi-nih-logo

Concept to Clinic: Commercializing Innovation (C3i) Program | National Institute of Biomedical Imaging and Bioengineering

By News Archive

nhlbi-nih-logo

The C3i Program is designed to provide medical device innovators with the specialized business frameworks and essential tools for successful translation of biomedical technologies from the lab (concept) to the market (clinic). Through this program, the NIH fosters the development and commercialization of early-stage biomedical technologies by engaging investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The curriculum and customized mentoring provided by the C3i Program are intended to guide investigators as they assess the commercial viability and potential business opportunity for their innovation.

Read More
rooster-bio-logo

RoosterBio Receives Grant from Maryland Stem Cell Research Fund to Commercialize MSC-EV Technology

By News Archive

rooster-bio-logo

RoosterBio, a regenerative medicine manufacturing technology leader, has received a $300,000 grant from the Maryland Stem Cell Research Commission to facilitate new product development. RoosterBio is one of three Maryland-based companies who received the Maryland Stem Cell Research Fund (MSCRF) Commercialization Program Award totaling $899,990 to assist with the creation of start-up companies or new technologies developed in Maryland.

Read More
prince-william-county-lunch-learn-logo

Lunch and Learn: Accessing the Virginia Neuroscience Initiative (VNI)

By News Archive

Wednesday, June 26, 2019 from 11:45 AM to 1:00 PM EDT

prince-william-county-lunch-learn-logo

Attendees will be provided an overview of Virginia Neuroscience (VNI) Initiative and how it accelerates neuroscience research by providing strategy, infrastructure, and research tools to clinicians, researchers, and industry. VNI members conduct basic and translational research in neurobiology to advance our understanding of brain diseases.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.